MDGL
Madrigal Pharmaceuticals, Inc.
Price Chart
Latest Quote
$509.76
-3.67 (-0.71%)
Current Price
| Previous Close | $513.43 |
| Open | $516.83 |
| Day High | $527.13 |
| Day Low | $509.06 |
| Volume | 399,750 |
Stock Information
| Shares Outstanding | 23.06M |
| Total Debt | $347.31M |
| Cash Equivalents | $812.77M |
| Revenue | $1.13B |
| Net Income | $-309.44M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $11.75B |
| EPS (TTM) | $-13.50 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $11.29B |
| Sales | $1.13B |
| Income | $-309.44M |
| Book/sh | $23.59 |
| Cash/sh | $35.25 |
| Employees | 915 |
Financial Ratios
| Quick Ratio | 2.96 |
| Current Ratio | 3.50 |
| Debt/Eq | 63.91 |
Returns & Margins
| ROA | -17.62% |
| ROE | -49.35% |
| Gross Margin | 93.07% |
| Operating Margin | -29.78% |
| Profit Margin | -27.32% |
Ownership
| Insider Ownership | 5.68% |
| Institutional Ownership | 106.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 41.18 |
| P/S | 10.38 |
| P/B | 21.61 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $678.71 |
Technical Indicators
| SMA20 | $492.81 |
| SMA50 | $509.12 |
| SMA200 | $494.57 |
| RSI | 61.51 |
| ATR | 17.4621 |
| Shares Float | 13.79M |
| Short Float | 19.50% |
| Short Ratio | 13.20 |
| Volatility | -1.06 |
| Rel Volume | 1.38 |
Performance History
| Week | +1.71% |
| Month | -1.45% |
| Quarter | +14.54% |
| 6 Months | -13.75% |
| YTD | -14.16% |
| Year | +80.13% |
| 3 Years | +108.84% |
| 5 Years | +382.59% |
| 10 Years | +5501.76% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $509.76 | 399,750 |
| 2026-06-23 | $513.43 | 266,400 |
| 2026-06-22 | $512.88 | 281,800 |
| 2026-06-18 | $505.75 | 487,000 |
| 2026-06-17 | $499.86 | 273,200 |
| 2026-06-16 | $501.19 | 319,900 |
| 2026-06-15 | $499.76 | 284,600 |
| 2026-06-12 | $480.77 | 207,500 |
| 2026-06-11 | $474.28 | 278,800 |
| 2026-06-10 | $471.32 | 287,500 |
| 2026-06-09 | $476.89 | 285,800 |
| 2026-06-08 | $467.28 | 262,700 |
| 2026-06-05 | $486.98 | 187,100 |
| 2026-06-04 | $492.83 | 219,100 |
| 2026-06-03 | $488.15 | 264,500 |
| 2026-06-02 | $452.86 | 427,200 |
| 2026-06-01 | $481.23 | 234,000 |
| 2026-05-29 | $497.27 | 436,000 |
| 2026-05-28 | $515.96 | 236,900 |
| 2026-05-27 | $527.67 | 144,100 |
| 2026-05-26 | $524.28 | 330,900 |
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
đ° Latest News
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Motley Fool âĸ 2026-06-16T07:50:00Z
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release
Simply Wall St. âĸ 2026-06-09T06:14:44Z
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Zacks âĸ 2026-06-05T15:30:24Z
Madrigal (MDGL) Data Highlights Rezdiffraâs Cardiometabolic Benefits for MASH Patients at EASL Congress
Insider Monkey âĸ 2026-06-04T09:07:08Z
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness
Simply Wall St. âĸ 2026-06-02T22:08:47Z
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
Motley Fool âĸ 2026-05-30T00:47:22Z
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
Motley Fool âĸ 2026-05-30T00:41:49Z
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth
Simply Wall St. âĸ 2026-05-10T19:08:09Z
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Zacks âĸ 2026-05-07T15:35:00Z
Madrigal Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-06T19:44:56Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $56,148,000 | $6,233,000 | $0 | $0 |
| Cost Of Revenue | $56,148,000 | $6,233,000 | $0 | $0 |
| Total Revenue | $958,403,000 | $180,133,000 | $0 | $0 |
| Operating Revenue | $958,403,000 | $180,133,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $22,309,000 | $14,671,000 | $12,712,000 | $3,964,000 |
| Total Expenses | $1,258,500,000 | $678,008,000 | $380,496,000 | $293,571,000 |
| Other Income Expense | $-3,242,000 | - | - | - |
| Other Non Operating Income Expenses | $-463,000 | - | - | - |
| Net Non Operating Interest Income Expense | $15,055,000 | $31,983,000 | $6,866,000 | $-1,779,000 |
| Interest Expense Non Operating | $22,309,000 | $14,671,000 | $12,712,000 | $3,964,000 |
| Operating Expense | $1,202,352,000 | $671,775,000 | $380,496,000 | $293,571,000 |
| General And Administrative Expense | - | - | $108,146,000 | $48,130,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-288,284,000 | $-465,892,000 | $-373,630,000 | $-295,350,000 |
| Net Interest Income | $15,055,000 | $31,983,000 | $6,866,000 | $-1,779,000 |
| Interest Income | $37,364,000 | $46,654,000 | $19,578,000 | $2,185,000 |
| Normalized Income | $-285,505,000 | $-465,892,000 | $-373,630,000 | $-295,350,000 |
| Net Income From Continuing And Discontinued Operation | $-288,284,000 | $-465,892,000 | $-373,630,000 | $-295,350,000 |
| Total Operating Income As Reported | $-300,097,000 | $-497,875,000 | $-380,496,000 | $-293,571,000 |
| Net Income Common Stockholders | $-288,284,000 | $-465,892,000 | $-373,630,000 | $-295,350,000 |
| Net Income | $-288,284,000 | $-465,892,000 | $-373,630,000 | $-295,350,000 |
| Net Income Including Noncontrolling Interests | $-288,284,000 | $-465,892,000 | $-373,630,000 | $-295,350,000 |
| Pretax Income | $-288,284,000 | $-465,892,000 | $-373,630,000 | $-295,350,000 |
| Special Income Charges | $-2,779,000 | $0 | $0 | - |
| Interest Income Non Operating | $37,364,000 | $46,654,000 | $19,578,000 | $2,185,000 |
| Operating Income | $-300,097,000 | $-497,875,000 | $-380,496,000 | $-293,571,000 |
| Gross Profit | $902,255,000 | $173,900,000 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-12.85 | $-21.90 | $-19.99 | $-17.23 |
| Basic EPS | $-12.85 | $-21.90 | $-19.99 | $-17.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-261,690,000 | $-450,125,000 | $-360,391,000 | $-290,919,000 |
| Total Unusual Items | $-2,779,000 | $0 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-2,779,000 | $0 | $0 | - |
| Reconciled Depreciation | $1,506,000 | $1,096,000 | $527,000 | $467,000 |
| EBITDA (Bullshit earnings) | $-264,469,000 | $-450,125,000 | $-360,391,000 | $-290,919,000 |
| EBIT | $-265,975,000 | $-451,221,000 | $-360,918,000 | $-291,386,000 |
| Diluted Average Shares | $22,434,310 | $21,272,962 | $18,687,774 | $17,137,201 |
| Basic Average Shares | $22,434,310 | $21,272,962 | $18,687,774 | $17,137,201 |
| Diluted NI Availto Com Stockholders | $-288,284,000 | $-465,892,000 | $-373,630,000 | $-295,350,000 |
| Other Special Charges | $2,779,000 | - | - | - |
| Research And Development | $388,525,000 | $236,718,000 | $272,350,000 | $245,441,000 |
| Selling General And Administration | $813,827,000 | $435,057,000 | $108,146,000 | $48,130,000 |
| Other Gand A | - | - | $108,146,000 | $48,130,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $595,308,000 | $749,654,000 | $405,333,000 | $197,389,000 |
| Total Assets | $1,259,589,000 | $1,042,247,000 | $640,547,000 | $362,572,000 |
| Total Non Current Assets | $13,819,000 | $9,320,000 | $3,266,000 | $1,203,000 |
| Goodwill And Other Intangible Assets | $7,381,000 | $4,729,000 | $0 | - |
| Current Assets | $1,245,770,000 | $1,032,927,000 | $637,281,000 | $361,369,000 |
| Other Current Assets | $47,804,000 | $13,786,000 | $3,150,000 | $2,595,000 |
| Restricted Cash | $5,090,000 | $5,000,000 | $0 | - |
| Inventory | $74,841,000 | $34,068,000 | $0 | - |
| Receivables | $134,476,000 | $53,822,000 | $0 | - |
| Accounts Receivable | $134,476,000 | $53,822,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $983,559,000 | $926,251,000 | $634,131,000 | $358,774,000 |
| Cash And Cash Equivalents | $198,693,000 | $100,019,000 | $99,915,000 | $331,549,000 |
| Cash Equivalents | - | - | $97,186,000 | $316,449,000 |
| Cash Financial | - | - | $2,729,000 | $15,100,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $141,188,000 | $17,550,000 | $15,565,000 | - |
| Total Debt | $347,630,000 | $119,570,000 | $117,193,000 | $49,891,000 |
| Long Term Debt And Capital Lease Obligation | $346,612,000 | $118,587,000 | $116,666,000 | $49,289,000 |
| Long Term Debt | $339,881,000 | $117,569,000 | $115,480,000 | $49,289,000 |
| Current Debt And Capital Lease Obligation | $1,018,000 | $983,000 | $527,000 | $602,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $656,900,000 | $287,864,000 | $235,214,000 | $165,183,000 |
| Total Non Current Liabilities Net Minority Interest | $346,612,000 | $118,587,000 | $116,666,000 | $49,289,000 |
| Current Liabilities | $310,288,000 | $169,277,000 | $118,548,000 | $115,894,000 |
| Payables And Accrued Expenses | $240,059,000 | $133,337,000 | $100,991,000 | $100,428,000 |
| Payables | $48,878,000 | $43,599,000 | $28,041,000 | $23,831,000 |
| Accounts Payable | $48,878,000 | $43,599,000 | $28,041,000 | $23,831,000 |
| Equity | ||||
| Common Stock Equity | $602,689,000 | $754,383,000 | $405,333,000 | $197,389,000 |
| Total Equity Gross Minority Interest | $602,689,000 | $754,383,000 | $405,333,000 | $197,389,000 |
| Stockholders Equity | $602,689,000 | $754,383,000 | $405,333,000 | $197,389,000 |
| Gains Losses Not Affecting Retained Earnings | $873,000 | $468,000 | $468,000 | $-32,000 |
| Other Equity Adjustments | $873,000 | $468,000 | $468,000 | $-32,000 |
| Retained Earnings | $-2,090,466,000 | $-1,802,182,000 | $-1,336,290,000 | $-962,660,000 |
| Other | ||||
| Ordinary Shares Number | $22,842,073 | $22,004,679 | $19,875,427 | $18,102,523 |
| Share Issued | $22,842,073 | $22,004,679 | $19,875,427 | $18,102,523 |
| Tangible Book Value | $595,308,000 | $749,654,000 | $405,333,000 | $197,389,000 |
| Invested Capital | $942,570,000 | $871,952,000 | $520,813,000 | $246,678,000 |
| Working Capital | $935,482,000 | $863,650,000 | $518,733,000 | $245,475,000 |
| Capital Lease Obligations | $7,749,000 | $2,001,000 | $1,713,000 | $602,000 |
| Total Capitalization | $942,570,000 | $871,952,000 | $520,813,000 | $246,678,000 |
| Additional Paid In Capital | $2,692,280,000 | $2,556,095,000 | $1,741,153,000 | $1,160,079,000 |
| Capital Stock | $2,000 | $2,000 | $2,000 | $2,000 |
| Common Stock | $2,000 | $2,000 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $6,731,000 | $1,018,000 | $1,186,000 | $0 |
| Current Capital Lease Obligation | $1,018,000 | $983,000 | $527,000 | $602,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $69,211,000 | $34,957,000 | $17,030,000 | $14,864,000 |
| Current Accrued Expenses | $191,181,000 | $89,738,000 | $72,950,000 | $76,597,000 |
| Net PPE | $6,438,000 | $4,591,000 | $3,266,000 | $1,203,000 |
| Gross PPE | $6,438,000 | $4,591,000 | $3,266,000 | $1,203,000 |
| Other Properties | $6,438,000 | $4,591,000 | $3,266,000 | $1,203,000 |
| Finished Goods | $7,208,000 | $4,535,000 | $0 | - |
| Work In Process | $67,633,000 | $29,533,000 | $0 | - |
| Raw Materials | $0 | $0 | $0 | - |
| Other Short Term Investments | $784,866,000 | $826,232,000 | $534,216,000 | $27,225,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-193,020,000 | $-462,034,000 | $-325,709,000 | $-225,074,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-189,553,000 | $-455,572,000 | $-324,230,000 | $-224,857,000 |
| Cash Flow From Continuing Operating Activities | $-189,553,000 | $-455,572,000 | $-324,230,000 | $-224,857,000 |
| Operating Gains Losses | $2,779,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-3,467,000 | $-6,462,000 | $-1,479,000 | $-217,000 |
| Investing Cash Flow | $32,320,000 | $-274,386,000 | $-502,520,000 | $206,686,000 |
| Cash Flow From Continuing Investing Activities | $32,320,000 | $-274,386,000 | $-502,520,000 | $206,686,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $397,487,000 | $260,187,000 | $255,382,000 |
| Financing Cash Flow | $255,984,000 | $735,062,000 | $595,116,000 | $313,451,000 |
| Cash Flow From Continuing Financing Activities | $255,984,000 | $735,062,000 | $595,116,000 | $313,451,000 |
| Net Other Financing Charges | $-10,407,000 | - | $-363,000 | $-886,000 |
| Net Common Stock Issuance | $0 | $397,487,000 | $260,187,000 | $255,382,000 |
| Common Stock Issuance | $0 | $397,487,000 | $260,187,000 | $255,382,000 |
| Other | ||||
| Repayment Of Debt | $-121,664,000 | $0 | $0 | - |
| Issuance Of Debt | $350,000,000 | $0 | $65,000,000 | $50,000,000 |
| End Cash Position | $203,783,000 | $105,019,000 | $99,915,000 | $331,549,000 |
| Beginning Cash Position | $105,019,000 | $99,915,000 | $331,549,000 | $36,269,000 |
| Effect Of Exchange Rate Changes | $13,000 | $0 | $0 | - |
| Changes In Cash | $98,751,000 | $5,104,000 | $-231,634,000 | $295,280,000 |
| Proceeds From Stock Option Exercised | $38,055,000 | $337,575,000 | $270,292,000 | $8,955,000 |
| Net Issuance Payments Of Debt | $228,336,000 | $0 | $65,000,000 | $50,000,000 |
| Net Long Term Debt Issuance | $228,336,000 | $0 | $65,000,000 | $50,000,000 |
| Long Term Debt Payments | $-121,664,000 | $0 | $0 | - |
| Long Term Debt Issuance | $350,000,000 | $0 | $65,000,000 | $50,000,000 |
| Net Investment Purchase And Sale | $35,787,000 | $-267,924,000 | $-501,041,000 | $206,903,000 |
| Sale Of Investment | $1,083,297,000 | $863,283,000 | $333,398,000 | $350,381,000 |
| Purchase Of Investment | $-1,047,510,000 | $-1,131,207,000 | $-834,439,000 | $-143,478,000 |
| Net Intangibles Purchase And Sale | $-3,000,000 | $-5,000,000 | $0 | $0 |
| Purchase Of Intangibles | $-3,000,000 | $-5,000,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-467,000 | $-1,462,000 | $-1,479,000 | $-217,000 |
| Purchase Of PPE | $-467,000 | $-1,462,000 | $-1,479,000 | $-217,000 |
| Change In Working Capital | $-8,498,000 | $-72,345,000 | $-3,276,000 | $37,604,000 |
| Change In Payables And Accrued Expense | $143,152,000 | $26,181,000 | $-2,721,000 | $38,861,000 |
| Change In Accrued Expense | $137,873,000 | $10,623,000 | $-6,931,000 | $36,410,000 |
| Change In Interest Payable | $5,971,000 | $-24,092,000 | $-5,450,000 | $-3,000 |
| Change In Payable | $5,279,000 | $15,558,000 | $4,210,000 | $2,451,000 |
| Change In Account Payable | $5,279,000 | $15,558,000 | $4,210,000 | $2,451,000 |
| Change In Prepaid Assets | $-34,018,000 | $-10,636,000 | $-555,000 | $-1,257,000 |
| Change In Inventory | $-36,978,000 | $-34,068,000 | $0 | $0 |
| Change In Receivables | $-80,654,000 | $-53,822,000 | $0 | $0 |
| Changes In Account Receivables | $-80,654,000 | $-53,822,000 | $0 | $0 |
| Other Non Cash Items | $4,814,000 | $1,689,000 | $2,414,000 | $797,000 |
| Stock Based Compensation | $98,130,000 | $79,880,000 | $49,735,000 | $31,625,000 |
| Depreciation Amortization Depletion | $1,506,000 | $1,096,000 | $527,000 | $467,000 |
| Depreciation And Amortization | $1,506,000 | $1,096,000 | $527,000 | $467,000 |
| Net Income From Continuing Operations | $-288,284,000 | $-465,892,000 | $-373,630,000 | $-295,350,000 |
Fetched: 2026-06-24